Krill oil, a marine supplement rich in omega-3 fatty acids and antioxidants, is often promoted for various health benefits, including potential support for liver health. Many people with fatty liver disease wonder whether krill oil might help reduce liver fat or slow disease progression. Whilst omega-3 supplements have been studied in non-alcoholic fatty liver disease (NAFLD), the evidence specifically for krill oil remains limited and inconclusive. NICE guidance does not currently recommend omega-3 supplements, including krill oil, for treating NAFLD. This article examines the current evidence, explores how krill oil might theoretically support liver health, and outlines proven lifestyle interventions that form the cornerstone of fatty liver management.

What Is Fatty Liver Disease and How Does It Develop?

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. Hepatic steatosis is present when fat is deposited in at least 5% of hepatocytes, confirmed by histology or equivalent imaging thresholds. The condition is broadly classified into two main types: non-alcoholic fatty liver disease (NAFLD), which affects individuals who drink little to no alcohol, and alcohol-related fatty liver disease (ARLD), caused by excessive alcohol consumption. NAFLD is increasingly common in the UK, affecting approximately one in three adults, often linked to metabolic syndrome.

The development of fatty liver is multifactorial. In NAFLD, insulin resistance plays a central role—when cells become less responsive to insulin, the liver increases fat production whilst simultaneously reducing fat breakdown. This metabolic dysfunction is frequently associated with obesity, type 2 diabetes, high cholesterol, and hypertension.

In its early stages, simple steatosis (fat accumulation alone) typically causes no symptoms and may be detected incidentally during imaging for other conditions. Importantly, liver function tests (LFTs) are often normal in NAFLD, so normal blood results do not exclude the condition. However, in approximately 20% of cases, NAFLD can progress to non-alcoholic steatohepatitis (NASH), characterised by inflammation and liver cell damage. Over time, NASH may lead to fibrosis (scarring), cirrhosis, and in severe cases, liver failure or hepatocellular carcinoma.

Risk factors include central obesity (particularly visceral fat), sedentary lifestyle, poor dietary habits (especially high intake of refined carbohydrates and saturated fats), and certain medications such as corticosteroids, tamoxifen, amiodarone, methotrexate, and valproate. Genetic predisposition also influences susceptibility, with variations in genes like PNPLA3 increasing risk.

NICE guidance (NG49) recommends risk stratification in adults with suspected NAFLD using non-invasive fibrosis scores such as the FIB-4 or NAFLD Fibrosis Score as a first-line assessment. If results are indeterminate or suggest increased risk, a second-line test such as the Enhanced Liver Fibrosis (ELF) blood test should be performed. Re-assessment is recommended approximately every three years in those with ongoing risk factors. Ultrasound may detect steatosis when clinically indicated but is not recommended for population screening.

Seek urgent medical assessment if you develop red-flag symptoms such as jaundice (yellowing of skin or eyes), new or worsening abdominal swelling (ascites), confusion or altered behaviour (hepatic encephalopathy), vomiting blood or passing black stools (gastrointestinal bleeding), severe abdominal pain, or signs of infection. Referral to a liver specialist (hepatologist) is appropriate if advanced fibrosis is suspected, fibrosis risk scores are high or uncertain, or there are atypical features requiring further investigation.

Does Krill Oil Help Fatty Liver? Current Evidence

Krill oil, derived from Antarctic krill (Euphausia superba), contains omega-3 polyunsaturated fatty acids—primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—bound to phospholipids rather than triglycerides. It also provides the antioxidant astaxanthin. Proponents suggest these components may benefit liver health, but current clinical evidence remains limited and inconclusive.

Several small-scale studies have investigated omega-3 fatty acids in NAFLD management. Systematic reviews and meta-analyses examining marine omega-3 supplementation have found modest improvements in liver fat content and some liver enzyme markers (ALT, AST) in certain trials. However, these studies predominantly used fish oil rather than krill oil specifically, and results have been inconsistent. The proposed mechanism involves omega-3s reducing hepatic lipogenesis (fat production), improving insulin sensitivity, and exerting anti-inflammatory effects through specialised pro-resolving mediators.

Regarding krill oil specifically, evidence is sparse and limited to very small studies. Human trials investigating krill oil in NAFLD are few, with small sample sizes and insufficient controls to draw firm conclusions. Animal studies have suggested potential benefits in reducing hepatic steatosis in mice, but extrapolation to humans requires caution. The phospholipid form of omega-3s in krill oil theoretically offers superior bioavailability compared to fish oil triglycerides, yet whether this translates to clinically meaningful liver benefits remains unproven.

NICE guidance (NG49) does not recommend omega-3 supplements, including krill oil, for the treatment of NAFLD. The evidence base is insufficient to support routine clinical use. It is important to note that krill oil is classified as a food supplement in the UK, not a licensed medicine, and is not subject to the same regulatory standards as prescription medications. Health claims for food supplements are restricted under UK and EU law.

Patients considering krill oil should discuss this with their GP, particularly if taking anticoagulants such as warfarin or antiplatelet medications, as omega-3 supplements may theoretically increase bleeding risk. This interaction is documented in the Summary of Product Characteristics (SmPC) for licensed omega-3 medicines such as Omacor (omega-3-acid ethyl esters), and monitoring may be advisable if supplements are used alongside antithrombotic therapy. There is no established clinical link between krill oil supplementation and significant improvement in fatty liver disease outcomes.

Alternative Treatments and Lifestyle Changes for Fatty Liver

The cornerstone of NAFLD management remains lifestyle modification, which has the strongest evidence base for improving liver health. Weight loss is the most effective intervention—studies demonstrate that losing 7–10% of body weight can significantly reduce liver fat, inflammation, and even fibrosis. This should be achieved gradually (0.5–1 kg per week) through sustainable dietary changes and increased physical activity.

Dietary recommendations aligned with NICE guidance include adopting a Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil, whilst limiting red meat, processed foods, and refined sugars. Reducing intake of fructose (particularly from sugar-sweetened beverages) is particularly important, as fructose metabolism in the liver promotes de novo lipogenesis. Saturated fat should be replaced with unsaturated fats. Some evidence suggests coffee consumption (2–3 cups daily) may have hepatoprotective effects, though this should not replace other interventions.

Physical activity independently improves liver fat content, even without significant weight loss. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic exercise weekly (or 75 minutes of vigorous activity), combined with muscle-strengthening activities on at least two days per week. Exercise enhances insulin sensitivity and promotes fat oxidation.

Alcohol consumption should be addressed according to the UK Chief Medical Officers' Low Risk Drinking Guidelines: no more than 14 units per week, spread over at least three days, with several alcohol-free days. In people with advanced liver disease or significant fibrosis, lower intake or abstinence is advisable. Even in NAFLD (non-alcohol-related), excessive alcohol can worsen liver damage.

Regarding pharmacological treatments, no medications are currently licensed specifically for NAFLD in the UK. NICE guidance (NG49) advises:

• Do not offer metformin solely for the purpose of treating NAFLD.

• Consider pioglitazone only in adults with biopsy-proven non-alcoholic steatohepatitis (NASH), after discussing the risks and benefits, including cardiovascular safety, bone health, and bladder cancer risk.

• Consider vitamin E (at a dose of 800 IU per day) only in adults without diabetes who have biopsy-proven NASH, after discussing potential long-term safety concerns.

Managing associated metabolic conditions is crucial: optimising glycaemic control in diabetes, treating dyslipidaemia with statins (which are safe and recommended in NAFLD), and controlling hypertension all contribute to overall cardiovascular and liver health.

Patients should avoid hepatotoxic substances and review medications with potential liver effects with their GP. NICE NG49 recommends fibrosis risk stratification using first-line tools such as FIB-4 or the NAFLD Fibrosis Score; if results are indeterminate or high risk, a second-line Enhanced Liver Fibrosis (ELF) blood test should be performed. Re-assessment is recommended approximately every three years in those with ongoing risk factors. Referral to hepatology is appropriate if advanced fibrosis is suspected, risk scores are high or indeterminate requiring specialist input, or there are atypical features or uncertainty about diagnosis.

How Krill Oil May Support Liver Health

Whilst definitive clinical evidence is lacking, several theoretical mechanisms suggest how krill oil might support liver health. It is important to emphasise that human evidence for krill oil improving NAFLD outcomes is insufficient, and these mechanisms remain largely hypothetical.

Omega-3 fatty acids in krill oil may influence hepatic lipid metabolism through multiple pathways. EPA and DHA activate peroxisome proliferator-activated receptors (PPARs), particularly PPAR-α, which upregulates genes involved in fatty acid oxidation whilst downregulating lipogenic enzymes like fatty acid synthase and acetyl-CoA carboxylase. This theoretically reduces hepatic triglyceride accumulation. Additionally, omega-3s may improve insulin signalling, addressing the underlying insulin resistance that drives NAFLD development.

The anti-inflammatory properties of marine omega-3s could theoretically benefit patients progressing from simple steatosis to NASH. EPA and DHA serve as precursors for resolvins, protectins, and maresins—specialised pro-resolving mediators that help resolve inflammation without immunosuppression. In NASH, chronic inflammation drives hepatocyte injury and fibrosis progression, so anti-inflammatory interventions hold theoretical appeal.

Astaxanthin, the carotenoid pigment giving krill oil its red colour, possesses antioxidant properties that may protect against oxidative stress—a key contributor to NAFLD progression. Oxidative stress occurs when reactive oxygen species overwhelm antioxidant defences, causing lipid peroxidation and cellular damage. Animal studies suggest astaxanthin may reduce hepatic oxidative stress markers, though human data are limited.

The phospholipid structure of omega-3s in krill oil may enhance bioavailability compared to fish oil triglycerides, potentially allowing lower doses to achieve similar tissue incorporation. However, whether superior bioavailability translates to clinical liver benefits remains unproven.

Important safety considerations: Krill oil is generally well-tolerated but may cause gastrointestinal upset, fishy aftertaste, or allergic reactions. Avoid krill oil if you have a shellfish or crustacean allergy. It may potentiate anticoagulant effects of warfarin or antiplatelet medications, increasing bleeding risk; if you choose to take krill oil alongside these medicines, discuss monitoring with your GP. Stop krill oil 1–2 weeks before elective surgery due to potential bleeding risk. Avoid during pregnancy and breastfeeding due to limited safety data. Krill oil should complement, not replace, evidence-based lifestyle interventions. If considering supplementation, choose products from reputable UK suppliers and do not exceed the recommended dose on the label. Remember that krill oil is a food supplement and is not subject to the same regulatory standards as licensed medicines; avoid products making therapeutic claims.

Report suspected adverse reactions: If you experience any suspected side effects from krill oil or any other medicine or supplement, you can report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or by searching for 'MHRA Yellow Card' in the Google Play or Apple App Store. There is currently no established clinical link between krill oil use and significant improvement in fatty liver disease.

Frequently Asked Questions